UCLA biotech spin-out ImmunGene receives $9m from life sciences investor Ally Bridge Group.

ImmunGene, a life sciences firm based in California, has raised $9m in series A backing through investment platform Ally Bridge Group.

The biotech, which is developing antibody-cytokine fusion technology therapies to treat cancer, is a spin-out of the University of California Los Angeles (UCLA). ImmunGene plans to use the latest funding to advance its products into further studies.

As part of the deal, ImmunGene welcomed two new members to its board of directors: Ally Bridge founder and chief executive Frank…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?